Physician profile
Brian Mannion
NPI 1851387039
$560.04
in general payments reported to CMS, 2019-2025
17 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $27.75 · 2022: $47.54 · 2023: $46.53 · 2024: $141 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $274 · Education: $42.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $274.21 |
| Education | $42.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Asd Specialty Healthcare, LLC | $70.62 | 2019 | |
| Incyte Corporation | $64.57 | 2024 | Jakafi |
| Blueprint Medicines Corporation | $55.00 | 2024 | Ayvakit |
| Exelixis INC. | $45.80 | 2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $39.40 | 2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $38.81 | 2019 | |
| Spectrum Pharmaceuticals INC. | $29.95 | 2023 | Rolvedon |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | Keytruda |
| Pharmacyclics LLC, An Abbvie Company | $25.44 | 2019 | |
| Janssen Biotech, INC. | $25.42 | 2019-2020 | |
| Genzyme Corporation | $24.91 | 2022 | |
| Alexion Pharmaceuticals, INC. | $22.63 | 2022 | |
| Tempus Ai, INC | $21.88 | 2024 | |
| Astellas Pharma US INC | $21.10 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $17.61 | 2025 | Sancuso |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $16.58 | 2023 | Opdivo |
| Astrazeneca Pharmaceuticals Lp | $14.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Mannion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.